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Abstract
Background: Mumps is a vaccine-preventable disease but outbreaks have been reported in persons vaccinated
with two doses of MMR vaccine.
The objective was to describe the demographic features, vaccination effectiveness and genetic mumps virus diversity
among laboratory-confirmed cases between 2007 and 2011 in Catalonia.
Methods: Cases and outbreaks of mumps notified to the notifiable diseases system of Catalonia between 2007 and
2011 retrospectively registered were included. Public health care centres provided written immunization records to
regional public health staff to determine the vaccination history.
Saliva and serum specimens were collected from suspected cases for laboratory-confirmation using real-time reverse-
transcriptase PCR (rtRT-PCR) or serological testing.
Phylogenetic analysis of the complete SH gene (316 nucleotides) and complete coding HN protein (1749 nucleotides)
sequences was made.
Categorical variables were compared using the Chi-square or Fisher’s tests and continuous variables using the Student
test. Vaccination effectiveness by number of MMR doses was estimated using the screening method.
Results: During the study period, 581 confirmed cases of mumps were notified (incidence rate 1.6 cases/100,000
persons-year), of which 60% were male. Three hundred sixty-four laboratory-confirmed cases were reported, of which
44% were confirmed by rtRT-PCR. Of the 289 laboratory-confirmed cases belonging to vaccination cohorts, 33.5% (97)
had received one dose of MMR vaccine and 50% (145) two doses.
Based on phylogenetic analyses of 316-nucleotide and 174-nucleotide SH sequences, the viruses belonging to viral
genotypes were: genotype G (126), genotype D (23), genotype H (2), genotype F (2), genotype J (1), while one
remained uncharacterized.
Amino acid differences were detected between circulating strains and the Jeryl Lynn vaccine strains, although the
majority of amino acid substitutions were genotype-specific.
Fifty-one outbreaks were notified that included 324 confirmed mumps cases. Genotype G was the most frequent genotype
detected. The family (35%), secondary schools (25%) and community outbreaks (18%) were the most frequent settings.
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Conclusions: Our study shows that genotype G viruses are the most prevalent in Catalonia. Most cases occurred in people
who had received two doses of MMR, suggesting inadequate effectiveness of the Jeryl Lynn vaccine strain. The possible
factors related are discussed.
Keywords: Mumps virus, Genotypes, Molecular surveillance, MMR vaccine, Laboratory diagnosis
Background
Mumps is a highly-contagious vaccine-preventable disease
caused by the mumps virus (MuV), an enveloped,
negative-strand RNA virus belonging to the Rubulavirus
genus of the Paramyxoviridae family. Infection is usually
benign and self-limited, but is sub-clinical and asymptom-
atic in up to 30% of cases. The main clinical manifestation
is parotitis, with one or both parotid glands involved.
However, mumps infection may also result in clinical
complications including aseptic meningitis, encephalitis
and orchitis, among others. In countries with high vaccin-
ation coverages, mumps incidence has dropped dramatic-
ally as has the percentage of cases with encephalitis and
other severe complications have been significantly re-
duced. Mumps disease shows epidemic peaks every 2 to 5
years [1]. Laboratory confirmation is based on the detec-
tion of MuV-specific immunoglobulin M (IgM) antibodies
in serum or saliva specimens, by viral isolation in cell cul-
ture, or by detection of viral genomic RNA in clinical
samples using molecular methods. Although MuV is con-
sidered to be serologically monotypic, distinct genetic
lineages of wild-type MuV have been reported to be co-
circulating. Up to 12 genotypes (A to N, excluding E and
M) are currently recognised based on sequence analysis of
the entire 316 nucleotides of the small hydrophobic (SH)
gene, including the non-coding regions flanking the cod-
ing sequence of the SH protein [2]. The hemmagglutinin-
neuraminidase (HN) gene encodes the protein that is the
main target of neutralising antibodies. According to
World Health Organization (WHO) guidelines, parallel
analysis of the HN sequence further supports the assign-
ment of genotyping based on SH gene sequencing, par-
ticularly when there is an ambiguous result [3, 4]. The
WHO recommends MuV genotyping as a tool for the dis-
tribution of the genetic lineages that co-circulate world-
wide and for viral epidemiological surveillance to trace the
patterns of virus spread.
The combined measles, mumps and rubella vaccine
(MMR) was included in the childhood immunization
schedule at 12 months in 1980 in Catalonia, an autono-
mous community in the north-eastern Spain with 7.5
million inhabitants, and was covered by public financing.
In 1987, administration of the first MMR dose was
switched from 12 to 15months, and reverted to 12
months in 2008. In 1988, a second dose of MMR was in-
cluded at 11 years, which was switched to 4 years in
1998. The incidence of mumps decreased significantly
from 456 to 3.6 cases per 100,000 persons-year between
1983 and 2011. Nevertheless, during the 2000s, several
MuV outbreaks were reported in spite of the > 95 and >
90% vaccination coverages for the first and second doses,
respectively, as reported in other countries with high
vaccination coverages [5–9].
The objective of this study was to describe the demo-
graphic features, vaccination effectiveness and genetic
MuV diversity of laboratory-confirmed cases from 2007
to 2011.
Methods
Patient population and study period
Descriptive study carried out with retrospectively registered
cases. From January 2007 to December 2011, suspected
cases of mumps were reported to the notifiable diseases sys-
tem of Catalonia. WHO case definitions were used to define
suspected and confirmed cases. A suspected case was de-
fined as an acute onset of unilateral or bilateral tender, self-
limiting swelling of the parotid or other salivary glands last-
ing ≥2 days without other apparent cause. A confirmed case
was defined as a laboratory-confirmed case or a case meet-
ing the clinical case definition and epidemiologically-linked
to a confirmed case [10]. A mumps outbreak was defined as
two or more cases linked by time and place within a max-
imum period of 26 days, one of which must be confirmed
by a laboratory [11]. For each case (sporadic cases and cases
related to outbreaks), field epidemiologists carried out an
epidemiological survey, according to routine procedures for
mumps surveillance in Catalonia, in which the following
variables were collected: birth date, gender, symptom onset
(parotitis), vaccination status, vaccine strain, sample collec-
tion date, and confirmatory diagnostic techniques. Public
healthcare centres supplied regional public health staff with
written immunization records to determine the vaccination
history.
The vaccine administered in the study period was the
Jeryl Lynn (JL) strain, except for a few years where the
Rubini and Urabe AM9 strains were administered. We
were unable to obtain the MMR vaccine composition
used in each study patient, but the birth cohort of cases
and the years when the strains were administered in
Catalonia were used as an approximation. The Urabe
strain was administered in 1991 and 1992. The first
Rubini vaccine dose was administered between 1994 and
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1995 (birth cohort 1993–1995), and the second Rubini
vaccine dose in 1994 and 1996 (birth cohort 1983 to
1985). We did not consider the administration of one or
two Rubini vaccine doses as valid immunization due to
its low immunogenicity. Therefore, only cases vaccinated
with the JL strain were included.
Laboratory-confirmation
Serum and saliva specimens were collected from sus-
pected cases for laboratory-confirmation using serological
or real-time reverse-transcriptase PCR (rtRT-PCR) test-
ing. Commercial enzyme-linked immunoassays (EIA) were
used, according to the manufacturer’s recommendations,
to detect MuV-specific IgG and IgM antibodies in serum
specimens. A real-time one-step RT-PCR assay with
primers and probe as previously described [12], was used
to detect viral RNA in saliva specimens. A minimum of 1
ml was collected after stimulation of the area of the par-
otid and salivary glands for 30 s. Samples were collected
preferably during the first 3 days of symptoms. rtRT-PCR
was the test of choice in all patients, especially those
previously-vaccinated, to avoid false-negative IgM anti-
body results in persons previously infected or immunized,
regardless of the timing of sample [3, 13, 14]. Total nucleic
acids were extracted from 200 μl of fresh specimen and
eluted in 25 μl of RNase-free elution buffer using bioMér-
ieux NucliSense easyMAG (bioMérieux, Marcy l’Etoile,
France) according to the manufacturer’s instructions.
Laboratory-confirmed specimens were kept frozen at −
80 °C for further analysis.
Phylogenetic analysis
The complete SH gene with flanking non-coding regions
(316 nucleotides) and complete coding HN protein
(1749 nucleotides) sequences was sequenced in parallel
for subsequent phylogenetic analyses to determine the
MuV genotype of laboratory-confirmed viruses. Amplifi-
cation of both viral regions was performed using the
One-step RT-PCR Kit (Qiagen, Hilden, Germany) for
one-step RT-PCR, the PCR Master Mix (Promega, Madi-
son, USA) for nested-PCR, and the primers and PCR
protocols as shown in Table 1. When there was non-
amplification of the 316-nucleotide SH region, the
complete coding SH sequence (174 nucleotides) was
amplified using the nested-PCR protocol described by
Palacios et al. [15]. PCR products were purified using
Exo-SAP-IT (USB, Affymetrix Inc. Cleveland, Ohio,
USA) and sequenced using the ABI Prism Big Dye Ter-
minator cycle sequencing kit v3.1 on the ABI PRISM
3130XL sequencer (Applied Biosystems, Foster City,
Table 1 Primer sequences and protocols for PCR amplification of complete coding SH gene with flanking non-coding sequence
(316 nucleotides) and complete coding HN protein sequences. Nucleotide positions are relative to AF338106 (major component
Jeryl-Lynn of live vaccine). The M13 primer binding sites used for sequencing are marked in bold




















Thermal profile: 96 °C × 1min - 30 cycles (96 °C × 10 s - 50 °C × 5 s - 60 °C × 4min)
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California, USA) using sequencing primers (Table 1)
[15]. Nucleotide sequences were edited and assembled
using SeqScape v2.5 software (Applied Biosystems, Fos-
ter City, California, USA) [12].
Phylogenetic analyses of SH and HN sequences were
carried out using the reference genotype sequences ac-
cording to WHO genotyping guidelines for mumps [2].
Molecular evolutionary models of nucleotide substitu-
tion were fitted to the multiple sequence alignments
using the evolutionary analyses conducted in MEGA
v5.2 [16]. The phylogenetic trees were reconstructed
using a neighbour-joining distance method as imple-
mented in MEGA v5.2 [16], with the evolutionary model
with the lowest Bayesian information criterion score.
The topological accuracy of the trees was evaluated by
the bootstrap method (1000 replicates).
The amino acid composition of the complete HN pro-
tein sequence was characterised relative to the homolo-
gous sequences of vaccine strains with accession numbers
AF338106 (major JL component of live vaccine),
AF345290 (minor JL component of live vaccine) and
X93180 (Rubini vaccine strain) using MEGA v5.2 [16].
Nucleotide sequences were collapsed to haplotypes using
ALignment Transformation EnviRonment (ALTER) to re-
duce redundant information [17] before being translated
to amino acid sequences to reveal the different circulating
genetic MuV variants even though translated amino acid
sequences were similar. The acquisition or loss of poten-
tial N-glycosylation sites in the complete amino acid se-
quence of the HN protein was tracked using N-GlycoSite
(www.hiv.lanl.gov). In addition, the genetic variability of
SH and HN sequences was studied within genotypes, be-
tween genotypes and relative to the major JL component
of the live vaccine (AF338106).
Statistical analysis
Categorical variables were compared using the Chi-
square or Fisher’s tests and continuous variables using
the Student test. Values of p < 0.05 were considered to
be statistically significant.
Vaccination effectiveness (VE) was calculated using all
confirmed cases born between 1982 and 2010. We ex-
cluded (a) children aged < 12 or 15months according to
the current childhood immunization schedule, (b) people
with unknown vaccination status and (c) people who had
received mumps-containing vaccine within 14 days of the
onset of mumps symptoms. VE was estimated using 433
eligible cases out of 581 confirmed cases. According to the
methodology described by Orenstein et al. [18], VE was
estimated using the screening method by the following
formula: VEi = 1- ((PCVi/1-PCVi) x (1-PPVi)/PPVi)), where
PCVi is the proportion of cases with i doses, PPVi is the
proportion of the population vaccinated with i doses, and
i is 1 or 2. 95% confidence intervals (CI) were calculated
using the Taylor series. To estimate the VE of one dose,
people who had received two doses were excluded from
the calculations of the proportions of cases and the popu-
lation vaccinated. Similarly, people who had received one
dose were excluded from calculations that estimated the
effectiveness of two doses.
The statistical analysis was made using SPSS/PC, ver-




From January 2007 to December 2011, 1175 suspected
cases of mumps disease were reported to the notifiable
diseases system of Catalonia, of which 581 (49%) were
confirmed cases (incidence rate of 1.6 cases/100,000
persons-year) (Table 2). 60% (347) were male with a
mean age 16.7 years (SD ± 10.9 years) and 40% (234)
were female with a mean age of 18.2 years (SD ± 13.6
years) (p = 0.08).
Fifty-nine percent of confirmed cases had a temperature
(≥38 °C). 3% presented orchitis and 0.5% encephalitis as
complications and 24 patients were hospitalized (median
2 days range: 1–5 days) (Additional file 1: Table S1).
Of the 364 laboratory-confirmed cases, 160 (44%) were
confirmed by rtRT-PCR assay, 174 (48%) by serological
assays and 30 (8%) using both techniques (Table 2). 55%
(201) of laboratory-confirmed cases were male and the
mean age was 19.3 years, SD ± 12.6 years (20.2 years in
females vs. 18.6 years in males, p = 0.2) and 217 were ep-
idemiologically linked to a laboratory-confirmed case.
Vaccination status and vaccine effectiveness
Of the 364 laboratory-confirmed cases, 297 (81.6%) had
criteria for MMR vaccination as they were born after
1980, when the childhood immunization schedule was
introduced in Catalonia. Of these, 49% (145) were vacci-
nated with two doses, 32.5% (97) with one dose, 14.5%
(43) did not receive MMR, the number of doses was un-
known in 1.3% (4) and information was missing in 2.7%
(8). Of the 67 remaining cases, 64 were born before
1980 and had had no opportunity for vaccination and
three cases occurred in children aged < 1 year (Table 2).
The VE was estimated in the 433 eligible cases out of
the 581 confirmed cases reported in Catalonia during
2007–2011. The point estimate of VE for one dose
ranged between 86.2% and 87.1% and for two doses be-
tween 87.6% and 89.3% (Table 3).
Distribution of MuV genotype
According to WHO guidelines [2] MuV genotyping was
successful in 147 (77%) of the 190 cases confirmed by
rtRT-PCR by phylogenetic analysis of complete coding
SH protein sequences with flanking non-coding regions
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Table 2 Characteristics of confirmed mumps cases and outbreaks according to circulating virus genotypes. Catalonia 2007–2011
CASES
Confirmed cases Laboratory-confirmed cases Genotype G Genotype D Othersa
N % N % N % N % N %
Gender 581 364 126 23 5
Male 347 59.7% 201 55.2% 78 61.9% 11 47.8% 4 80.0%
Female 234 40.3% 163 44.8% 48 38.1% 12 52.2% 1 20.0%
Age group (years)
< 1 4 0.7% 2 0.5% 0 0.0% 0 0.0% 0 0.0%
1–4 69 11.9% 34 9.3% 3 2.4% 5 21.7% 0 0.0%
5–14 209 36.0% 116 31.9% 32 25.4% 13 56.5% 3 60.0%
15–24 173 29.8% 111 30.5% 56 44.4% 1 4.3% 0 0.0%
25–34 75 12.9% 78 21.4% 28 22.2% 4 17.4% 1 20.0%
≥ 35 51 8.8% 23 6.3% 7 5.6% 0 0.0% 1 20.0%
Year
2007 272 46.8% 204 56.0% 90 71.4% 1 4.3% 1 20.0%
2008 85 14.6% 56 15.4% 2 1.6% 10 43.5% 3 60.0%
2009 56 9.6% 22 6.0% 8 6.3% 1 4.3% 1 20.0%
2010 68 11.7% 30 8.2% 5 4.0% 8 34.8% 0 0.0%
2011 100 17.2% 52 14.3% 21 16.7% 3 13.0% 0 0.0%
Laboratory tests 364 62.6%
rtRT-PCR assays 160 44.0% 108 85.7% 22 95.7% 4 80.0%
IgM assays 166 45.6% – – –
Both tests 30 8.2% 18 14.3% 1 4.3% 1 20.0%
Seroconversion 8 2.2% – – –
Epidemiologically-linked cases 217 37.4% 364
Vaccination status
Non-vacinated 150 25.8% 110 30.2% 34 27.0% 8 34.8% 2 40.0%
One MMR dose 85 14.6% 97 26.6% 39 31.0% 4 17.4% 0 0.0%
Two MMR doses 314 54.0% 145 39.8% 52 41.3% 10 43.5% 3 60.0%
Unknown number 15 2.6% 4 1.1% 1 0.8% 0 0.0% 0 0.0%
Missing information 17 2.9% 8 2.2% 0 0.0% 1 4.3% 0 0.0%
Complications
Orchitis 20 3.4% 19 5.2% 7 5.6% 0 0.0% 0 0.0%
Encephalitis 3 0.5% 3 0.8% 0 0.0% 0 0.0% 0 0.0%
Fever 344 59.2% 235 64.6% 83 65.4% 7 30.4% 3 100.0%
Time since second dose of MMR vaccine
0–5 years 89 28.3% 45 31.1% 9 17.3% 4 40.0% 1 33.3%
≥ 6 years 225 71.7% 100 68.9% 43 82.7% 6 60.0% 2 66.7%
OUTBREAKS Number of outbreaks Outbreak related cases Genotype G Genotype D Othersa
N % N % N % N % N %
Total outbreaks 51b _ 324 _ 20 _ 4 _ 3 _
Year
2007 31 60.8% 166 51.2% 16 80.0% 0 0.0% 1 33.3%
2008 11 21.6% 39 12.0% 0 0.0% 2 50.0% 2 66.7%
2009 2 3.9% 9 2.8% 2 10.0% 0 0.0% 0 0.0%
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(316 nucleotides) (Fig. 1). In addition, phylogenetic ana-
lysis was also performed in another 8 (4%) cases based
on complete coding SH sequences (174 nucleotides)
(Additional file 4: Figure S1), showing robust, phylogen-
etic analysis results (bootstrap values > 70%) even
though the length of sequences was shorter than recom-
mended by the WHO for characterisation. According to
the phylogenetic analyses of the 316-nucleotide (Fig. 1)
or 174-nucleotide (Additional file 4: Figure S1) SH se-
quences, genotype frequencies were: 126 (81%) genotype
G, 23 (15%) genotype D, 2 (1%) genotype H, 2 (1%)
genotype F, 1 (< 1%) genotype J and 1 (< 1%) unclassified
(Table 2). MuV genotyping based on complete coding
HN sequences (Additional file 5: Figure S2) was consist-
ent with the results obtained from SH sequences. The
remaining 35 (18%) cases of MuV could not be geno-
typed due to non-amplification of SH or HN regions,
likely due to the low viral load or the low quality of gen-
etic material from laboratory-confirmed clinical samples.
The genetic variability of nucleotide and deduced
amino acid SH and HN sequences of laboratory-
confirmed samples was also studied (Additional file 2:
Table S2). The 155 complete 174-nucleotide SH se-
quences were collapsed into 35 (23%) haplotypes, while
the 110 complete coding HN sequences were collapsed
into 38 (35%) haplotypes despite being longer (1749 nu-
cleotides). Within genotypes, the complete coding SH
sequences showed greater mean genetic divergences
(0.49–6.90%) than the complete coding HN sequences
(0.18–3.09%). The mean genetic distances between se-
quences within genotypes relative to the sequences from
the major component of the JL vaccine strain are shown
as additional information (Additional file 2: Table S2).
The deduced amino acid sequences of the complete
coding HN region that were collapsed into haplotypes
were compared with the major component of the JL
and other vaccine strains (Table 4). Up to 6 amino
acid differences were found, but there was no gain or
loss of potential N-glycosylation positions within anti-
genic regions (amino acid positions 265–288, 329–340
and 352–360) previously characterised. In addition, up
to 9 other amino acid changes were found within
other viral HN regions where some amino acid sub-
stitutions were previously related to immune escape
from neutralisation [19]. No amino acid changes
(K335E/R, P/Q354H, E/D356S, R360C, N464K, and
S466 N) in other sites previously associated with
neurovirulence were detected [20].
Nucleotide sequences were submitted to the
GenBank database (accession numbers KX609797-
KX609951).
Temporal distribution of outbreaks
In 2007–2011, 51 outbreaks of mumps were notified,
with 324 confirmed cases. Most occurred in 2007 (61%)
and 2008 (22%). The most frequent settings were the
family (35%), with a mean size of 2.3 cases, secondary
schools (25%) with a mean size of 4.3 cases, and
Table 2 Characteristics of confirmed mumps cases and outbreaks according to circulating virus genotypes. Catalonia 2007–2011
(Continued)
2010 3 5.9% 19 5.9% 1 5.0% 2 50.0% 0 0.0%
2011 4 7.8% 91 28.1% 1 5.0% 0 0.0% 0 0.0%
Setting
Family 18 35.3% 42 13.0% 7 35.0% 1 25.0% 0 0.0%
Secondary 13 25.5% 56 17.3% 3 15.0% 1 25.0% 1 33.3%
High school 8 15.7% 168 51.9% 3 15.0% 2 50.0% 1 33.3%
Occupational 3 5.9% 7 2.2% 1 5.0% 0 0.0% 1 33.3%
Community (discotheque, football team, neighbours) 9 17.6% 51 15.7% 6 30.0% 0 0.0% 0 0.0%
aOthers: Genotype F, Genotype H and Genotype J
bIn 21 outbreaks the genotype was not known and 3 outbreaks were not typable”
Table 3 Estimates of vaccine effectiveness for one and two doses of the MMR vaccine by birth cohort of all confirmed cases of
mumps. Catalonia 2007–2011
Number of cases Vaccine effectiveness (95%CI)
Birth cohort No vaccine One dose Two doses One dose Two doses
1982–1991 32 35 73 87.1 (79.2–92,1) 89.3 (83.7–92.9)
1992–2001a 10 52 132 86.8 (74.1–93.3) 87.6 (75,4- 93,7)
2002–2010b 12 51 36 86.2 (74.2–92.7) 88.5 (76.1–94,4)
n = 581 (433 cases targeted for vaccination; 116 cases non-targeted for vaccination, 15 unknown number and 17 cases missing information)
a To calculate the effectiveness of the second dose, birth cohorts from 1994 to 1996 were excluded as the MMR vaccine administered contained the Rubini strain
b Estimates of VE for two doses were birth cohorts from 2002 to 2008
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community outbreaks in young adults (discotheque,
football team, etc.) (18%) with a mean size of 5.7. Eight
(16%) outbreaks occurred in high schools, with a mean
size of 21 (Table 2).
Phylogenetic analysis was carried out in 30 outbreaks:
the genotype detected was G in 20 outbreaks, D in 4
outbreaks and F, H and J in one outbreak each, while
three outbreaks were non-typable (Table 2 and Fig. 2).
Genotype G viruses circulated throughout the study
period at variable levels, affecting 99 confirmed cases
(Fig. 2). In 2007, genotype G viruses were predominant
with 16 (80%) outbreaks that affected 74 confirmed
cases, constituting an epidemic wave but during 2008–
2011 their circulation decreased (3 outbreaks with 25
confirmed cases). This was considered an inter-epidemic
period. Genotypes D, F, H and J also co-circulated dur-
ing the inter-epidemic period (Fig. 2).
Discussion
This study found five different MuV genotypes. Of the
more than 1100 suspected cases, almost half were con-
firmed by laboratory methods or epidemiological link-
age. In clinical parotitis, causes other than the mumps
virus should be considered. In a previous study, we
found that approximately 51% of suspected cases of
mumps infection were laboratory-confirmed for infec-
tion by other viruses such as the Epstein-Bar virus, para-
influenza viruses or adenovirus [21].
About 70% of laboratory-confirmed mumps cases were
vaccinated, with a mean age of 14.3 years (SD ± 7.3), of
whom 40% received two recommended JL vaccine doses.
Phylogenetic analyses of SH and HN sequences revealed
that the genotypes most frequently detected were G and
D. In Spain, the emergence and spread of genotype G vi-
ruses since 2006 has been reported [22], and virological
surveillance shows continuity until 2011 due to the find-
ings of the present study. The circulation of the geno-
type G virus has been reported in outbreaks in Europe
and USA, and particularly in patients vaccinated with
two doses of MMR [6, 7, 19, 23–27]. Our results suggest
that genotype G viruses are highly prevalent and have a
substantial capacity to spread among the vaccinated
population. Mumps cases have continued to occur after
our study period, presenting as multiannual waves. Re-
cent data suggest that in 2015, a new epidemic wave
began in Catalonia, with genotype G being the most
prevalent. This behaviour was also observed in the rest
of Spain, where 57% of cases with a vaccination history
had received ≥1 vaccine dose [28, 29].
A possible explanation might be the antigenic differ-
ences between the circulating and vaccine strains (im-
mune escape) [30, 31], or progressive loss of protective
antibodies over time (waning immunity). Other authors
Fig. 1 Phylogenetic reconstruction of complete coding SH gene. The
strains in the present study are coloured by year: 2007 (orange), 2008
(red), 2009 (pink), 2010 (blue) and 2011 (brown)
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have suggested high-density, close-contact environments
such as schools or universities as likely causes [6, 9, 32].
With respect to the differences detected between the
circulating and JL vaccine strains, the alignment of de-
duced amino acid sequences revealed that most amino
acid substitutions were genotype-specific.
Some reports suggest that neutralising antibodies are spe-
cific to the vaccine strain used, and humoral protection is not
sufficiently efficient to prevent infection by MuVs from differ-
ent genotypes and disease progression. Geographical differ-
ences between circulating genotypes and the vaccine strain
have been reported worldwide. In the Western Hemisphere,
the composition is mainly based on the JL strain (genotype
A) and, in a few countries, on the Urabe AM9 (genotype B)
and Leningrad-Zagreb (genotype N) strains, whereas the
wild-type viruses currently circulating predominantly belong
to genotype G strains. Some authors have found that neutra-
lising epitopes were vaccine strain-specific and, therefore, vac-
cination did not completely prevent mumps disease and
complications by viruses belonging to genotypes other than
the vaccine genotypes [31]. Our results show that viruses be-
longing to five genotypes were co-circulating in the study
period at varying levels despite high community vaccination
coverage with the JL vaccine (mean of 94.2% for the second
dose). Although our results suggest immune escape by the
acquisition of amino acid substitutions within the antigenic
epitopes of the HN protein, they also indicate a possible loss
of immunity or secondary vaccine failure. Several factors sup-
port this explanation. First, waning immunity was linked to
the time since vaccination [26, 33]. In our study, 72% of con-
firmed cases received the second dose of MMR ≥6 years be-
fore symptom onset. Secondly, the VE in observational
studies of the JL strain (75%–82% for a single dose and 79%–
95% for two doses) [3, 34–39] is lower than the efficacies re-
ported in clinical trials (92%–96%) [40, 41]. Similarly, the
point estimate of VE for all confirmed cases during the study
period ranged between 86% and 87% for one dose and 88%–
89% for two doses. Thirdly, 58% of laboratory-confirmed pa-
tients were aged > 15 years, and only 10% were aged < 5 years;
this is consistent with other studies that found an upsurge of
cases in young adults [24, 25], which is in accordance with a
decrease in neutralising antibody levels over time, as reported
in seroepidemiological studies, which probably result in in-
complete protection against heterologous MuV strains [24,
42]. This may be explained, at the beginning of the vaccin-
ation period, by the fact that vaccinated persons had natural
reinfection due to the circulating virus. When rates of disease
incidence fell to low levels, the possibility of boosting was
Table 4 Molecular characterization of deduced amino acid positions in HN protein. The nucleotide sequences were previously
collapsed into haplotypes, and the numbers of sequences represented are shown in brackets with the name in the first column.
Potential n-glycosylation positions are highlighted in grey. Amino acids other than the deduced reference sequence (AF338106) are
shown with a dot
Amino acid position previously associated with neurovirulence; Ag Amino acid position within antigenic region, NE Neutralisation-escape position
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reduced. In Finland, a vaccination coverage of > 95% main-
tained over time permitted the elimination of endemic trans-
mission of the virus in 1996 [43]. If low titres of neutralising
antibodies are an important factor in outbreaks, it is essential
to have a threshold titre to determine the response of anti-
mumps antibodies and whether the subject is fully protected
against wild virus infection [44].
Outbreaks have been reported in populations vacci-
nated with the JL vaccine strain, but also with the Urabe
AM9 and Leningrad-Zagreb vaccines [45]. Therefore,
the development of a new mumps vaccine would prob-
ably not be the solution to the current problem. Instead,
revaccination with a third vaccine dose in adolescents
could repair the loss of immunity, as other authors have
reported [1]. At present, the CDCs recommend a third
dose of MMR as a post-exposure measure to control
outbreaks [33, 46–48].
We found that SH and HN sequencing provided
the same genotyping results in most MuV infections.
The comparison of mean genetic divergence within
genotypes, the genetic distances relative to the JL vac-
cine strain, and the percentage of collapse into haplo-
types, revealed that the coding SH protein sequence
is more variable than the coding HN protein
sequence at the nucleotide and amino acid levels, as
reported by other authors [19]. Despite the lower di-
versity of the HN protein compared with the SH pro-
tein, its molecular characterisation is highly
recommended to detect viral variants with changes
that affect mainly antigenic epitopes [49].
The availability of nucleotide sequences might help to
trace the person-to-person chain of transmission in epi-
demiological investigations of outbreaks in the future. A
global sequence database and mumps strain bank similar
to the Measles Nucleotide Surveillance (MeaNS) data-
base should be developed to facilitate the distribution of
sequence variants of MuV, which is particularly import-
ant to link endemic cases to imported cases from other
countries and monitor the spread of novel genetic viral
variants with new antigenic features on the HN or the F
proteins.
One limitation of the study is that detection of the
virus by rtRT-PCR was more frequent in persons who
had received two doses of MMR than in unvaccinated
persons. This might be due to the fact that, although
rtRT-PCR is the test of choice, if epidemiologists know
that the suspected case had received the vaccine they
prioritize a rtRT-PCR test because, in vaccinated people,
Fig. 2 Distribution of outbreaks of mumps and outbreak-related cases according to genotype and year of detection. Catalonia 2007–2011. Others:
Genotype F, Genotype H and Genotype J
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false-negative serology results (IgM antibody) are fre-
quent (Additional file 3: Table S3).
Conclusions
Our study, carried out with retrospective cases, shows that
genotype G viruses are the most prevalent in Catalonia and
may be transmitted within a highly-vaccinated population.
Most cases occurred in people who had received two doses
of MMR, suggesting inadequate effectiveness of the JL vac-
cine strain. The possible factors related to the decrease in
vaccine effectiveness include secondary vaccine failure (wan-
ing immunity), intense exposure to the virus due to social
overcrowding, and a possible mismatch between the vaccine
genotype and that of circulating mumps virus strains.
Molecular and epidemiological studies are needed to
provide information on the factors related to vaccine
failure in countries with high vaccine coverages.
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